<template>
  <div class="main-container">
    <HeaderAria />

    <div
      class="blog-pages-wrapper"
      style="padding-top: 50px; padding-bottom: 50px"
    >
      <div class="container">
        <div class="row">
          <div class="col-lg-12">
            <!-- Post Feature Start -->
            <div class="post-feature blog-thumbnail wow move-up">
              <img
                class="img-fluid"
                src="/images/aria/blogTwo.jpg"
                alt="Aria Blog - Vipin Adhlakha"
              />
            </div>
            <!-- Post Feature End -->
          </div>
          <div class="col-lg-8 ml-auto mr-auto">
            <div class="main-blog-wrap">
              <!--======= Single Blog Item Start ========-->
              <div class="single-blog-item wow move-up">
                <!-- Post info Start -->
                <div class="post-info lg-blog-post-info">
                  <div class="post-categories text-center">
                    <n-link to="/blog"> Aria Diagnostics </n-link>
                  </div>

                  <h3 class="post-title text-center">
                    Rethinking the Necessity of D and L Isomer Testing as a
                    Follow-Up to Positive Methamphetamine Results in LCMS Urine
                    Drug Testing
                  </h3>

                  <div class="post-excerpt mt-15">
                    <p>
                      In recent years, there has been a growing debate
                      surrounding the need for D and L isomer testing as a
                      follow-up to positive methamphetamine results in liquid
                      chromatography-mass spectrometry (LCMS) urine drug
                      testing. The reflex to D and L testing following positive
                      methamphetamine results has been considered standard
                      practice. However, scientific evidence and an evaluation
                      of the benefits of D/L testing do not outweigh the
                      drawbacks.
                    </p>

                    <blockquote>
                      <p class="p1">
                        Methamphetamine is metabolized in the body primarily
                        into its D-isomer, d-methamphetamine, which is the
                        active component responsible for the drug's psychoactive
                        effects. The L-isomer, l-methamphetamine, is a less
                        potent and biologically inactive form which may also be
                        present in illicit methamphetamine. Thus the presence of
                        any d-methamphetamine in urine serves as a reliable
                        indicator of methamphetamine use.
                      </p>
                    </blockquote>

                    <p>
                      LCMS urine drug testing is a highly sensitive and
                      selective method for detecting methamphetamine and its
                      metabolites. Studies have shown that LCMS reliably
                      identifies d-methamphetamine (the isomer most commonly
                      detected on routine LCMS drug testing panels) which is
                      sufficient evidence of recent methamphetamine use. Given
                      the sensitivity of this testing method, the need for
                      additional D and L isomer testing may be unnecessary to
                      determine illicit drug use. Differentiating between D and
                      L isomers requires specialized analytical methods, such as
                      chiral chromatography, which are not routinely employed in
                      standard LCMS urine drug testing protocols since it
                      requires unique sample preparation and testing technology.
                      Incorporating D and L isomer testing adds complexity to
                      laboratory procedures, requiring additional time,
                      resources, and expertise. Moreover, these specialized
                      tests come at a higher cost and are typically not covered
                      by insurance benefits thereby placing an unnecessary
                      burden on patients.
                    </p>

                    <p>
                      From a clinical standpoint, distinguishing between
                      d-methamphetamine and l-methamphetamine does not provide
                      meaningful information for patient management. The
                      presence of d-methamphetamine indicates recent
                      methamphetamine use, which is the critical factor in
                      assessing compliance or addressing substance abuse issues.
                      The identification of l-methamphetamine does not
                      contribute to the clinical interpretation nor rule out the
                      use of methamphetamine.
                    </p>

                    <p>
                      Professional guidelines and consensus statements support
                      the limited clinical value of D and L isomer testing
                      following positive methamphetamine results. The Substance
                      Abuse and Mental Health Services Administration (SAMHSA)
                      guidelines do not require D and L isomer testing as a
                      routine follow-up for methamphetamine detection in
                      workplace drug testing programs. These guidelines
                      emphasize the importance of accurate detection of
                      d-methamphetamine without necessitating the additional
                      isomer testing.
                    </p>
                    <p>
                      Based on the scientific evidence presented, it is
                      suggested that providers utilizing drug testing for
                      patient care reassess the need for D and L isomer testing
                      and consider evidence-based approaches that prioritize
                      accurate detection of d-methamphetamine while minimizing
                      unnecessary financial burden on patient. By aligning with
                      current scientific consensus, we can ensure that drug
                      testing practices are efficient, cost-effective, and
                      rooted in the best interests of patients and the wider
                      healthcare community.
                    </p>
                    <a
                      href="https://vipinadhlakha.com/"
                      target="_blank"
                      style="color: red"
                      >Vipin Adhlakha - CEO Aria Diagnostics</a
                    >
                    <!-- <h5 style="padding-top: 10px">Resources:</h5>
                    <a
                      href="https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/674%20Drug%20Testing%20in%20Pain%20Management%20and%20Substance%20Use%20Disorder%20Treatment%20prn.pdf"
                      >Blue Cross Blue Shield. Medical Policy: Urine Drug
                      Testing in Pain Management and Substance Use Disorder
                      Treatment.</a
                    >
                    <a
                      href="https://www.cms.gov/medicare/medicare-fee-for-service-payment/clinicallabfeesched"
                      >Centers for Medicare and Medicaid Services. Clinical
                      Laboratory Improvement Amendments (CLIA).</a
                    > -->
                  </div>
                </div>
                <!-- Post info End -->
              </div>
              <!--===== Single Blog Item End =========-->
            </div>
          </div>
        </div>
      </div>
    </div>

    <AriaFooter />

    <OffCanvasMobileMenu />
  </div>
</template>

<script>
import data from "../data/blog.json";
import HeaderAria from "@/components/aria/HeaderAria";
import AriaFooter from "@/components/aria/AriaFooter";
import OffCanvasMobileMenu from "@/components/OffCanvasMobileMenu";

export default {
  components: {
    HeaderAria,
    AriaFooter,
    OffCanvasMobileMenu,
  },
  data() {
    return {
      data,
    };
  },
  head() {
    return {
      title: "Aria Blog - Vipin Adhlakha",
      meta: [
        { hid: "og-type", property: "og:type", content: "website" },
        {
          hid: "description",
          name: "description",
          content:
            "In recent years, there has been a growing debate surrounding the need for D and L isomer testing",
        },
        {
          hid: "og:title",
          property: "og:title",
          content:
            "Rethinking the Necessity of D and L Isomer Testing as a Follow-Up to Positive Methamphetamine Results in LCMS Urine Drug Testing",
        },
        {
          hid: "og:description",
          property: "og:description",
          content:
            "In recent years, there has been a growing debate surrounding the need for D and L isomer testing",
        },
        {
          hid: "og:image",
          property: "og:image",
          content: "https://www.ariadxs.com/images/aria/blogTwo.jpg",
        },
        {
          hid: "og:url",
          property: "og:url",
          content: "https://www.ariadxs.com/rethinking-the-necessity",
        },
        {
          hid: "twitter:title",
          name: "twitter:title",
          content: "Aria Blog - Vipin Adhlakha",
        },
        {
          hid: "twitter:description",
          name: "twitter:description",
          content:
            "In recent years, there has been a growing debate surrounding the need for D and L isomer testing",
        },
        {
          hid: "twitter:image",
          name: "twitter:image",
          content: "https://www.ariadxs.com/images/aria/blogTwo.jpg",
        },
        {
          hid: "twitter:card",
          name: "twitter:card",
          content: "summary_large_image",
        },
        { hid: "t-type", name: "twitter:card", content: "summary_large_image" },
      ],
    };
  },
};
</script>
